Soligenix (NASDAQ: SNGX) , a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. Th ...

Traws Pharma, Inc. ( NASDAQ: TRAW) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - ...

Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, ...

Doctors and scientists who spoke to HuffPost are worried for a multitude of reasons and want you to know that this will ...

MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ:MDAI) reports second quarter earnings just weeks after ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

VANGUARD has selected five companies for up to $200,000 in non-dilutive funding contracts and 10 companies for the 2025 ...

Reports Q2 revenue $2.7M vs. $57,000 last year. “Traws has made good progress this year towards our goal of bringing our antiviral candidates to ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ...

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

What makes this doubly frustrating is that Kennedy and his back-to-the-past approach to public health would be better off ...